Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide
and is associated with high case fatality rates and serious life-long complications among …

The epidemiology of invasive meningococcal disease continues to change rapidly, even in
the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease …

Meningococcal outer membrane proteins have been used for over 20 years in more than 80
million doses; either as carrier protein in a Haemophilus influenzae type b (Hib) …

The discovery of vaccine antigens through whole genome sequencing (WGS) contrasts with
the classical hypothesis-driven laboratory-based analysis of microbes to identify …

The utility of wild-type outer membrane vesicle (wtOMV) vaccines against serogroup B
(MenB) meningococcal disease has been explored since the 1970s. Public health …

This review article incorporates information from the 4th Global Meningococcal Initiative
summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown …

Background. In the absence of an efficacious broadly protective vaccine, serogroup B
Neisseria meningitidis (MenB) is the leading cause of bacterial meningitis and septicemia in …

No broadly effective vaccines are available for prevention of group B meningococcal
disease, which accounts for> 50% of all cases. The group B capsule is an autoantigen and …

It has been demonstrated that antibodies induced by meningococcal polysaccharide,
polysaccharide-protein conjugates and outer membrane protein vaccines protect against …

Background: An investigational vaccine against serogroup B meningococcal (MenB)
disease containing 3 main recombinant proteins (factor H-binding protein, Neisserial …